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SUMMARY 
Synthetic genes encoding bovine and human basic tibroblast growth factors (bFGFs) were assembled and 
cloned using established Escherichiu coli expression plasmids. Transformed E. coli cells were able to synthesize 
either a fusion protein, comprising the first seven amino acids of p-galactosidase, a linker fragment and bovine 
FGF, or genomic human bFGF. The two growth factors were purified from E. coli lysates by cation exchange 
and heparin-Sepharose affinity chromatography. The purified recombinant proteins were biologically active as 
monitored by their mitogenic activity for bovine aortic endothelial cells and their angiogenic capacity in the 
rabbit cornea. 
INTRODUCTION 
The growth of the new capillaries (angiogenesis) is 
a complex process which involves both the migration 
and proliferation of vascular endothelial cells 
(Folkman, 1985). The vascular endothelium of a 
normal adult organism rejuvenates only a few times. 
On the other hand, a rapid turnover can be seen in 
various pathophysiological responses such as acute 
inflammation, wound healing, and tumor angio- 
genesis (Folkman and Klagsbrun, 1987). Basic FGF 
(bFGF) has been shown to be a very potent mitogen 
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and chemoattractant for endothelial cells in vitro (for 
review, see Gospodarowicz et al., 1986). It stimu- 
lates angiogenesis in vivo on the chick chorioal- 
lantoic membrane and rabbit cornea (for review, see 
Folkman and Klagsbrun, 1987). 
Bovine bFGF has been purified and characterized 
from a wide range of tissues including pituitary, 
brain, hypothal~us, retina, adrenal gland, thymus, 
corpus luteum, and kidney (Lobb et al., 1986; 
Gospodarowicz et al., 1986). Although the amino 
acid and nucleotide sequences of both bovine and 
human bFGF are known (Abraham et al., 1986), 
little protein material has up to now been available. 
It is therefore desirable to produce sufficient quanti- 
ties of recombinant bFGF to be able to tackle 
questions concerning the biological role of signals 
that naturally trigger angiogenesis in vivo or to obtain 
sufficient growth-factor protein for use as an (essen- 
tial) component for serum-free cell-culture medium. 
Here we report the design, assembly, and expres- 
sion of synthetic genes encoding bovine and human 
bFGFs. Since bFGF is a single-chain non glyco- 
sylated polypeptide, it seemed reasonable to expect 
that biolo~cally active material might be produced in 
E. coli. Two different vector systems were used to 
obtain synthesis of the factors in fused and unfused 
forms. An initial step toward optimization of the 
direct expression of human bFGF was taken by 
manipulating the N-terminal part of the synthetic 
gene so as to allow efficient r~slational initiation in 
the pJLA503 expression vector. 
MATERIALS AND METHODS 
(a) Reagents and enzymes 
Restriction endonucleases and BSA were pur- 
chased from Boehringer Mannheim. Bacteriophage 
T4 DNA ligase, polynucleotide kinase, PolIk, 
nucleic-acid-grade agarose, heparin-Sepharose, 
CLdB; CM-Sephadex C-50, Bio-Gel-P2, and 
NAP-10 columns were obtained from Pharmacia. 
Diisopropyl phosphoramidites were obtained from 
Applied Biosystems, phosphotriester reagents were 
obtained from Biosearch; [a-3SS]dATP and 
[ Y-~*P]ATP were obtained from Amersham; DEAE 
NA45 membranes and nitrocellulose filters were 
purchased from Schleicher & Schuell; the x-ray films 
RX were obtained from Fuji; Costar plates were 
obtained from Costar, Cambridge, MA; PBS, 
DMEM, and trypsin-EDTA solution were obtained 
from Gibco; peroxidase-conjugated goat anti-rabbit 
IgG antibody was purchased from Medac; and 
Biorad protein assay was obtained from Biorad. 
(b) Synthesis and puri~catioR of oiigodeoxynacle- 
otides 
Oligos 1-26 were synthesized using phospho- 
triester chemistry on the Biosearch model Cyclone 
oligo synthesizer. Oligos were purified by electro- 
phoresis on 12% to 20% poiyacrylamide gel under 
denaturing conditions. Gel-purified oligos were 
eluted from the gel in water and desalted on NAP-10 
columns. 
(c) Phosphoryiati~ and tigation of oIig~xy~ucle- 
otides 
Oligos used in the assembly of the synthetic bFGF 
gene were phosphorylated as follows: 500 ng of each 
purified oligo with the exception of numbers 1, 8, 9, 
14, 15, 22, 23, and 26 were incubated in 10 1.11 of 
70 mM Tris . HCl, pH 7.6, 10 mM MgCl,, 5 mM 
DTT, 10pM ATP, and 0.15 PM [y-3ZP]ATP 
(specific activity 6000 Ci/mmol) containing 10 units 
of T4 polynucleotide kinase. After 1 h at 37°C the 
kinase was inactivated by heating to 95 *C for 2 min. 
After separating labeled DNA from unincorporated 
[ y-32P]ATP by chromatography through small 
columns of Bio-Gel-P2, the following subsets of 
oligos were mixed for ligation to the fragments A, B, 
C, and C’, respectively: oligos Nos. 1-8, 9-14, 
15-22, and 23-26. The indicated subsets were 
heated to 80’ C for 10 min and then slowly cooled to 
25°C over 1 h to allow the complementary strands 
to anneal. 
Each solution was adjusted to 70 mM Tris * HCI 
pH 7.2, 100 mM NaCl, 10 mM MgCl,, 1 mM 
EDTA, and 5 mM DTT. Then 0.5 mM ATP T4 
DNA ligase was added to 0.8 units per 10 ~1 and the 
reaction mixture was incubated overnight at 16°C. 
Fragments A, B, and C were purified in a 7 M 
ureafl2% polyacryl~ide gel run in 90 mM Tris, 
90 mM borate, and 2 mM EDTA. The wet gel was 
autoradiographed overnight and the detected DNA 
fragments were electroeluted into dialysis bags. 
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Each gel-purified fragment was incubated in 10 ~1 
of 50 mM Tris * HCl, pH 7.6, 10 mM MgCl,, 5 mM 
DTT, 0.1 mM spermidine, 0.1 mM EDTA, 
0.125 mM ATP, and 10 units of T4 polynucleotide 
kinase. After 1 h at 37 o C, the kinase was inactivated 
by heating to 95 ‘C for 2 min. 
The cloning of the kinased fragments took place as 
follows: fragment A was ligated to EcoRI + &I- 
digested M13mp18; fragment B to &I + XbaI- 
digested pGem 4, and fragment C, C’ to 
XbaI + HindIII-digested M13mp18 using a 10: 1 
molar ratio of insert : vector. Each double-digested 
vector DNA was dephosphorylated prior to the 
insert ligation in 30 ~1 of 50 mM Tris . HCl, pH 9.5, 
50 mM Tris . HCl, pH 9.5, 50 mM NaCl, 0.5 mM 
DTT, containing 1 pg digested vector DNA and 1 
unit of calf intestinal phosphatase. After incubation 
for 1 h at 50°C the enzyme was inactivated by 
adding 2 ~1 of 0.5 mM EDTA. 
(d) Plasmid construction and DNA cloning 
Standard procedures were used for plasmid purili- 
cation (Birnboim and Doly, 1979), transformation 
(Mandel and Higa, 1970) and DNA sequencing 
(Sanger et al., 1977). Large plasmid fragments were 
separated by agarose gel electrophoresis followed by 
electroelution on DEAE-NA45 membranes. 
(e) Isolation of recombinant basic fibroblast growth 
factor 
(1) Cell lysis 
250 ml of an appropriate culture was centrifuged 
for 15 min at 4000 rev./min. and 0” C. The cell pellet 
was resuspended in 4 ml buffer L (50 mM Tris . HCl, 
pH 8.0, 10 mM EDTA) containing 25% sucrose. 
After adding 6 mg lysozyme in 1.2 ml buffer L and 
2.4mlof0.25 M EDTA,0.25MTris.HCl,pH 8.0, 
the mixture was incubated for 1 h at 0’ C. Then 10 ml 
of 2% Triton X-100 in buffer L was added and, 
following sonication at O”C, soluble and insoluble 
material was separated by centrifugation for 17 min 
at 6000 rev./min. The pellet containing bFGF in- 
clusion bodies was washed twice with 2% Triton 
X-100 in buffer L and used for purification (see 
subsection 3, below). 
(2) Purification of soluble FGF 
The supernatant remaining after cell lysis (see sub- 
section I, above) was applied to a CM Sephadex 
C-50 column (10 ml bed volume, diameter 4 cm, flow 
rate 100 ml/h, at room temperature), washed with 
0.1 M Na. phosphate, pH 6.5, 0.15 M NaCl, and 
eluted with 0.1 M Na* phosphate, pH 6.5, 0.6 M 
NaCl. The eluate was applied to heparin-Sepharose 
column (2 ml bed volume, diameter 1 cm, flow rate 
50 ml/h). The column was washed with 10 mM 
Tris . HCl, pH 7.0, 0.8 M NaCl and eluted with 
10 mM Tris . HCl, pH 7.0, 2.0 M NaCl. The eluate 
was dialysed against 50 mM ammonium formate 
and lyophilized. 
(3) Preparation of bFGFfrom inclusion bodies 
The washed pellet obtained after cell lysis (see 
subsection 1, above) was solubilized in 10 ml buffer 
L containing 6 M guanidinium. HCl and 0.25 M 
DTT and incubated for 2 h at 50°C. Buffer L (30 ml) 
was then added slowly with vigorous stirring and 
simultaneous slow cooling to 30°C. After dialyzing 
against 10 mM Tris . HCl, pH 7.0, 0.8 M NaCl and 
subsequent centrifugation, the supernatant was 
applied directly to a heparin-Sepharose column as 
described above. 
(f) Preparation of rabbit anti-bovine basic fibroblast 
growth factor 
A peptide corresponding to the 19 aa 
(FPPGHFKDPKRLYCKNGGF) near the N ter- 
minus of bovine bFGF (Esch et al., 1985) was 
synthesized by solid-phase methods using a 
Biosearch peptide synthesizer. The synthetic peptide 
was purified by reverse-phase HPLC and then 
coupled to BSA using 1-ethyl-3-(3-dimethylamino- 
propyl) carbodiimide (EDC; Shapira et al., 1984). 
Rabbits were immunized with 0.5 mg of the BSA- 
peptide conjugate emulsified with complete Freund’s 
adjuvant. Three weeks later, a booster injection was 
given using 0.3 mg of the conjugate emulsified in 
incomplete Freud’s adjuvant. Sera were tested by 
Western blot analysis (see section b, below) using 
bovine brain-derived bFGF. 
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(g) SDS-PAGE and silver staining 
Growth factor fractions from various purification 
steps were dialyzed against 50 mM ammonium 
formate overnight, lyophilized, boiled in sample buf- 
fer, and analyzed on SDS-15% PAGE (Laemmli, 
1970). After electrophoresis the polypeptide bands 
were visualized by silver staining (Oakley et al., 
1980). 
(j) In vivo assay 
Heparin-Sepharose-purified recombinant bFGF 
in Elvax polymers (Langer et al., 1986) was 
implanted into rabbit cornea1 pockets as described 
(Gimbrone et al., 1974; Risau, 1986). 
RESULTS AND DISCUSSION 
(h) Western-blot analysis 
For Western immunoblotting analysis, electro- 
phoretically separated polypeptides were transferred 
onto nitrocellulose at 0.3 mA/cm2 in 20 mM Tris, 
pH 7.4, 150 mM glycine, and 20% methanol over- 
night (Towbin et al., 1979). To block nonspecific 
binding, the nitrocellulose was incubated with PBS 
containing 3 y0 B SA for 1 h at room temperature and 
washed twice with PBS containing 0.1 y0 Tween-20. 
The first antibody reaction was carried out by 
incubating the nitrocellulose with a lOOO-fold dilu- 
tion of the rabbit anti-bovine bFGF antibody in PBS 
containing 0.1 y0 Tween-20 and 1 y0 BSA for 2 h at 
room temperature followed by 3 washing steps with 
PBS containing 0.1% Tween-20. The nitrocellulose 
was then incubated with a 500-fold dilution of the 
peroxidase-conjugated goat anti-rabbit IgG antibody 
for 1 h at room temperature followed by washing. 
The immunoreaction was visualized using 
0.5 mg/ml diaminobenzidine . HCl in 50 mM 
Tris’ HCl, pH 7.6, 100 mM NaCl, 0.4% nickel 
sulfate, and 0.01% H,O,. 
(i) Proliferation assay 
Fractions were assayed for growth factor activity 
on BAE cells as described (Risau, 1986). Briefly, 
cells were resuspended in DMEM supplemented 
with 4% FCS, glutamine (0.5 mg/ml), and 
penicillin/streptomycin (100 units/ml), and plated 
(10000 cells/O.5 ml per well) on 24-well plates. 
Unattached cells were removed one day later and 
0.5 ml of fresh supplemented DMEM containing 
growth-factor fractions was added. After three days 
of incubation, cells were detached from the plates 
using trypsin/EDTA solution and counted in a 
coulter counter. 
(a) Construction of the bovine and human bFGF 
gene 
A synthetic gene encoding the 146 aa of bovine 
bFGF was designed on the basis of the known amino 
acid sequence (Esch et al., 1985). The selection of 
the precise nucleotide sequence for the gene was 
influenced by the following considerations: (1) The 
high frequency of a set of statistically ‘preferred’ 
codons among highly expressed E. coli genes; (2) the 
obvious convenience of introducing unique restric- 
tion endonuclease recognition sites into the se- 
quence; and (3) the need to avoid the presence of 
excessively stable secondary structures in the en- 
coded mRNA, especially in the early part of the 
cistron. 
Twenty-two oligos ranging in size from 24 to 52 nt 
were synthesized, purified, and assembled to form 
the synthetic bovine bFGF gene (Fig. 1). To assemble 
the gene, subsets of oligos were ligated to generate 
the fragments A, B, and C. These fragments were 
purified by PAGE under denaturing conditions, 
phosphorylated, and ligated to appropriately 
digested, dephosphorylated vectors. The resulting 
hybrid plasmids were transferred into E. coli cells. 
Clones containing the predicted DNA inserts as 
determined by double-digestion of the respective 
plasmid DNA were selected for the preparation of 
larger quantities of the A, B, and C fragments, which 
were subsequently isolated and annealed. The result- 
ing synthetic gene was ligated to EcoRI + HindII- 
digested pUC8 and used to transform E. coli HB 10 1. 
A clone containing the predicted nucleotide se- 
quence, as determined by Sanger et al. (1977) se- 
quencing, was designated pUC8ABC. 
The synthetic gene encoding the 146 aa of the 
human bFGF was initially constructed by exchang- 
ing fragment C of pUC8ABC for a further fragment 
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C’ (Fig. 1) that was synthesized according to the 
published sequence of human bFGF (Abraham 
et al., 1986). N-terminally extended forms of the 
gene were constructed by exchanging the first part 
of the synthetic sequence with appropriate oligo 
pairs. 
(b) Expression of basic fibroblast growth factor 
Plasmid pUC12, an M13mp7-derived system 
(Vieira and Messing, 1982), was doubly digested 
with SmaI + HindIII, dephosphorylated, and ligated 
Prominent polypeptides with apparent M,.s of 
(1) (3) 
Pro Ala Leu Pro Glu Asp Gly Gly Ser Gly Ala Phe Pro Pro Gly His 
5' A ATT CCC GGG CCA GCT CTG CCG GAA FAC GGT GGT TCT GGT GCT TTC CCC CCG GGT CAC 
3' GGG CCC AAG GGIG GGC CCA GTG 
t t 
GGT CGA GAC GGC CTT CTG CCA CCA AGA CCA CGA 
(2) 
EcoR I Hae III 
(5) 
Phe Lys Asp Pro Lys Arg Leu Tyr Cys Lys Asn Gly Gly Phe Phe Leu Arg Ile His 
TTC AAA GAC CCG AAA CGL CTG TAC TGC AAA AAC GGT GGT TTC TTC CTG CGT ATC CAC 
AAG TTT CTG GGC TTT GCA GAC ATG ACG TTT TTG CCA CCA A(AG AAG GAC GCA TAG GTG 
(4) 
(7) 
Pro Asp Gly Arg Val Asp Gly Val Arg Glu Lys Ser Asp Pro His Ile Lys Leu Gln 
CCG GAC GGT C]GT GTT GAC GGT GTT CGT GAA AAA TCC GAC CCG CAC ATC AAA CTC CAA 
GGC CTG CCA GCA CAA CTG CCA CAA GCA CTT TTTl AGG CTG GGC GTG TAG TTT GAG GTT 
(6) (8) 
(9) 
Leu Gln Ala Glu Glu Arg Gly 
GTT GAA GAA CGT GGT 
CGA CTT CTT GCA CCA 
t 
Pst I 
Leu Ala Met Lys Glu Asp Gly 
CTG GCT ATG AAA GAA GAC GGT 
GAC CGA TAC TTT CTT CTG CCA 
Phe Phe Phe Glu Arg Leu Glu 
TTC TTC TTT GAA CGT 




Val Val Ser Ile Lys Gly Val Cys Ala Asn Arq Tyr 
GTT GTT TCIC ATC AAA GGT GTT TGC GCT AAC CGT TAC 
CAA CAA AGG GAG TTT CCA CAA ACG CGA TTG GIjA ATG 
(10) 
(13) 
Arg Leu Leu Ala Ser Lys Cys Val Thr Asp Glu Cys 
CjGT CTG CTG GCT TCC AAA TGC GTT ACC GAC GAR TGC 
GCA GAC GAC CGA AGG TTT ACG CAA T~G'G CTG CTT ACG 
(12) 
(15) 
Ser Asn Asn Thr Asn Thr Thr Arg Ser Arg Lys Thr 
TCC AAC AAC TAC AAC ACC TlAC CGT TCC CGT AAA TAC 
AGG TTG TTG ATG TTG TGG ATG GCA AGG GCA TTT ATG 
(16) 
(19) (17) 
Ser Ser Trp Tyr Val Ala Leu Lys Arg Thr Gly Gln Tyr Lys Leu Gly Pro Lys Thr 
TCC TCC TGG TAC GTT GCT CTG AAA CGT ACC GGT CAG TAC AAA CTG GGT CCG AAA ACC 
_mGG ACC ATG CAA CGA GAC TTT F;;)TGG CCA 'GTC ATG TTT GAC CCA &GC TTTl TGG 
Gly Pro Gly Gln Lys Ala Ile Leu Phe Leu Pro Met Ser Ala Lys Ser * * 
GGT CCG GGT CAG AAA (GCT ATC CTG TTC CTG CCG ATG TCC GCT AAA TCC TAA TA 
CCA GGC CCA GTC TTT CGA TAG GAC AAG GAC G& TAC AGG CGA TTT AGG ATT ATT CGA 
(20) (22) t 
Hind III 
Fig. 1. Nucleotide sequence of the synthetic bovine bFGF gene. Numbers in parentheses identify the 22 oligos used in the gene assembly. 
The lines denote the ends of the oligos and the respective overlapping regions between fragments. Unique restriction sites are marked 
by upward arrows. Asterisks represent stop codons. The human bFGF nucleotide sequence was obtained by exchanging the underlined 
base pairs T/A of a Ser codon and C/G of a Pro codon into A/T and T/A, respectively, resulting in codons for Thr and Ser. 
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with the HaeIII-Hind111 fragment of pUC8ABC 
containing the synthetic bovine bFGF nucleotide 
sequence. The r sulting recombinant plasmid LD l/2 
encodes a 156-aa fusion protein consisting of the first 
7 aa of #I-galactosidase, 3 aa encoded by part of the 
multiple cloning site, and the 146 aa of bovine 
bFGF. 
Computer analysis of the translational initiation 
region of the pUC12-bbFGF encoded mRNA 
predicted a highly stable (dG at 37 “C = -14 kcal) 
hairpin loop structure immediately adjacent to the 
Shine-Dalgarno region (Fig. 2a). Such a structure 
would be expected to impinge on translational 
initiation (see, e.g., McCarthy and Bokelmann, 
1988). 
In the case of human bFGF a number of con- 
structs differing in the nature of the N-terminal part 
of the synthetic gene were subjected to analysis. 
Extra codons, corresponding to part or all of the 
N-terminal extension to the 146-aa form of bFGF 
identified by nucleotide sequencing (Abraham et al., 
1986), were included in these constructs. One con- 
struct encoded the full 155 aa described by Abraham 
et al. (1986). The extra N-terminal sequence was 
borne on an N&I-Hind111 DNA fragment, whereby 
the codon usage was adjusted to prevent the forma- 
tion of highly stable secondary structure within the 
translational initiation region formed upon insertion 
a 
of this new synthetic gene into the expression vector 
pJLA503 (Fig. 2b). The 155-codon gene, containing 
the NdeI-Hind111 fragment, was initially subcloned 
into pCB179 (Schneider and Beck, 1987). It was 
subsequently excised as an NdeI-Sal1 fragment and 
inserted into appropriately cleaved pJLA503. The 
latter expression vector is one of a series of plasmids 
derived from pJLl20 1 bearing part of the E. coli atpE 
TIR (McCarthy et al., 1986; Schauder et al., 1987). 
Transcription in these plasmids is initiated by the 
1 bacteriophage major pR and pL promoters (in 
tandem) and is repressed by the product of the 
plasmid-borne cIts857 gene. 
Correct recombinant products, bearing the fused 
bovine bFGF in pUC12 (LD1/2) and the unfused, 
fully extended human bFGF in pJLA503 (T36/9), 
were transferred into E. coli cells (strain 
R1180:sc122, Ion-, htpR_). Transcription of the 
human bFGF gene was repressed by the A cIts875- 
coded repressor when cultures of R1180-T36/9 were 
grown at 30°C. A temperature shift from 30°C to 
42°C allowed synthesis of large amounts of human 
bFGF via inactivation of the A cIts857-coded 
repressor (Fig. 3). Cultures of R1180[pJLA503] 
(vector minus DNA insert) grown at 30’ C and 42’ C 
served as controls. The bovine bFGF fusion protein 
encoded by LD1/2 was expressed constitutively in 
strain R1180. 
b 
Fig. 2. Secondary structures predicted for the mRNA TIRs encoded by (a) pUC12-bbFGF and (b) pJLA503-hbFGF (Zuker and 
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Fig. 3. SDS-15% PAGE analysis ofrecombinant bFGF expres- 
sion. Cultures of pUC12 (vector only) and LD1/2 (vector + 
bFGF) were grown overnight at 37°C (final A,,, nm = 4); cul- 
tures of pJLA503 (vector only) and T36/9 (vector + bFGF) 
E. coli R1180 were grown at 30°C (A 1), then induced for 3 h at 
42” C (A 2). Each culture was then diluted to an A of 0.5; 40 ~1 
along with 20 ~1 of loading buffer were boiled for 10 min. Of each 
sample solution 10 ~1 were loaded onto the gel. Lanes: a and I, 
molecular size protein standards (in kDa, as indicated at the 
left); b, Rll80 cells, 37°C; E, Rll80[pUCl2] DNA, 37°C; d, 
Rll8O[pUClZ-bbFGF], 37°C; e, Rll80 cells, 30°C; f, Rll80 
cells, 42°C; g, Rll80[pJLA503] DNA, 30°C; b, Rll80- 
[pJLA503], 42°C; i, Rll80[pJLA503-hbFGF], 30°C; k, Rll80- 
[pJLA503-hbFGF], 42°C. The arrows indicate the protein 
encoded by pUCl2bbFGF (lane d) and by pJLA503-hbFGF 
(lane k), respectively. 
18 kDa and 20.5 kDa were present in extracts of 
induced E. coli cultures of R1180[T36/9] and 
R1180[LD1/2], respectively. These proteins were 
absent in extracts from control cultures. 
Recombinant growth factors were purified from 
E. coli cells using a procedure established for the 
purification of bFGF from bovine brain (Lobb et al., 
1986; Risau et al., 1988). Cells were lysed by a com- 
bination of Triton X-100 and mild lysozyme treat- 
ment. Following sonication the extracts were clari- 
lied by centrifugation. 
The supernatant was applied to a CM-Sephadex 
C-50 cation exchange column. The column was 
washed and growth factor activity eluted using 0.6 M 
NaCl. Heparin-Sepharose affinity chromatography 
was used as the second step in purification. Almost 
all of the extraneous protein present in the Sephadex 
eluate was separated from growth factor activity in 
this second step. The FGF activity itself could be 
eluted using 2 M NaCl. Sephadex and subsequent 
heparin-Sepharose-purified growth factor fractions 
were analyzed by the SDS-PAGE, followed by 
silver staining or immunoblotting using polyclonal 
antibodies prepared against a bFGF peptide. Cells 
transformed by LD l/2 plasmid encoding the bovine 
bFGF/B-galactosidase fusion protein synthesized a 
protein of 20.5 kDa (Fig. 4a), which is the expected 
size calculated from the encoded mRNA. 
Recombinant human bFGF encoded by the plas- 
mid T36/9 should have an J4, of 18 000 and a protein 
of approximately this size could be observed after 
induction (Fig. 4b). Natural bovine brain bFGF 
served as a control (Fig. 4a). An immunoreactive 
peptide of lower M,, probably a product of proteoly- 
tic degradation, was also detected using the anti- 
body. Recombinant bovine bFGF fusion protein 
appeared as a doublet (Fig. 4a), a phenomenon that 
has also been described for the brain-derived bovine 
bFGF (Lobb et al., 1986). 
FGF was also present in cytoplasmic inclusion 
bodies, as is often observed with other recombinant 
proteins expressed at a high level in E. coli (Kleid 
et al., 1981; Simons et al., 1984; Schoner et al., 
1985). Proteins in such inclusion bodies are generally 
soluble only under denaturing conditions. Thus, the 
pellet fraction obtained after centrifugation of lysed 
cells was solubilized in a large volume of 
guanidinium . HCl together with 0.2 M DTT to 
cleave possible intermolecular disulfide bonds. For 
renaturation the treated pellet fraction was carefully 
diluted and dialysed to prevent aggregation of 
bFGF. The cleared dialysate was directly applied to 
a heparin-Sepharose affinity column as described 
above. 
(c) Biological activities of bovine and human recom- 
binant fibroblast growth factor 
The purified growth factors were analyzed for 
mitogenic activity on BAE cells. In this assay, the 
maximal stimulation observed with brain-derived 
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Fig. 4. SDS-PAGE and Western blot analysis of different FGF purification steps. Samples containing about 1 pg protein were separated 
by SDS-15% PAGE, transferred onto nitrocellulose, incubated with anti-bFGF antibodies, and then reacted with a peroxidase- 
conjugated goat anti-rabbit IgG antibody. (Panel A) Bovine bFGF: lanes a-d, silver stained peptides; e-h, immunoblot; a, molecular 
size protein standards (kDa as indicated at the left); b,f, CM Sephadex CSO eluate; c,g,h, heparin-Sepharose eluate; d,e, brain-derived 
bovine bFGF. (Panel B) Human bFGF: lanes: a-d, silver stained peptides; a, cell lysate (R118O[pJLA503-hbFGF], 42°C); b, CM 
Sephadex C50 eluate; c, heparin-Sepharose eluate; d, molecular size protein standards (kDa as indicated between lanes d and e); e, 
immunoblot, heparin-Sepharose eluate. 
bFGF, as were the concentrations giving half- 
maximal stimulation [ED,, brain-derived bovine 
bFGF 0.2 ng/ml, ED,, recombinant human bFGF 
(isolated from the supematant) 0.14 rig/ml] (Fig. 5). 
The recombinant human bFGF isolated from the 
pellet fraction showed a somewhat lower ED,, of 
0.5 ng/ml. The lower specific activity of the human 
bFGF pellet preparation might be due to the incom- 
plete formation of disultide bonds that may be 
important to the correct conformation of bFGF (cf., 
e.g., aFGF; Thomas et al., 1988). The recombinant 
bovine bFGF fusion protein showed an ED,, of 
0.95 ng/ml, probably owing to the presence of addi- 
tional p-galactosidase amino acids at the N terminus 
of the molecule. 
We also examined the in vivo activity of recombi- 
nant bovine bFGF fusion protein and the human 
bFGF. In rabbit corneas, new sprouts originating 
from the limbal vascular system penetrated the 
avascular cornea two days after implantation of 
Elvax polymers cont~ning 500 ng of recombin~t 
human bFGF and reached the polymer ten days later 
(Fig. 6). Similarly, recombinant bovine bFGF fusion 
protein stimulated angiogenesis in the rabbit cornea 
(not shown). No neovascularization was seen in 
corneas in which control polymers had been 
implanted. No inflammation was observed, except 
for an initial slight cloudiness of some corneas, which 
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Fig. 5. Proliferation of BAE cells as a function of medium 
supplement (DMEM supplemented with calf serum and different 
bFGF preparations). IO“ cells/20 mm well were seeded in Costar 
plates as described in MATERIALS AND METHODS, section 
i. Cells were exposed to medium containing 4% FCS and increas- 
ing amounts of growth-factor fractions. +, Brain-derived (BD) 
bovine bFGF, ED,,, 0.2 ng/ml; A, recombinant bovine bFGF 
fusion protein, supernatant (SN) ED,,, 0.95 ng/ml; 0, recombi- 
nant human bFGF, supernatant ED,,, 0.14 ng/ml; n , recombi- 
nant human bFGF, pellet (P) ED,,, 0.5 ng/ml. 
Fig. 6. Angiogenic activity of recombinant human bFGF. Elvax 
pellets containing 500 ng protein of the heparin-Sepharose puri- 
fied recombinant bFGF along with rabbit serum albumin to 
achieve 20% loading of the polymer were implanted into rabbit 
cornea1 pockets (four corneas). Capillaries were seen invading 
the cornea after two days and reached the polymers approx. ten 
days later. The photograph was taken 18 days after implantation, 
Bar, 1 mm. 
Biologically active recombinant bovine bFGF 
fusion protein and human bFGF encoded by chemi- 
cally synthesized genes were isolated in high yield 
and high purity. They were obtained as a single band 
on SDS-PAGE (Fig. 4a,b). Quantitation of the 
expressed growth factors was carried out using the 
Biorad protein assay. 
The described plasmid constructions in the 
selected E. coli strains directed the synthesis of 
0.5 mg bovine bFGF protein and 5 mg human 
bFGF protein per liter culture medium per 1 AhOOnm 
isolated from the soluble fraction of the cell extracts. 
Three to four times the quantity of biologically 
active growth factor protein could certainly be 
obtained from the insoluble material that is also 
present in the induced cells. This would necessitate 
the successful renaturation of solubilized inclusion 
bodies. Large quantities of recombinant bFGF 
should help us to elucidate the biological function of 
bFGF in vivo as well as to investigate its potential 
application under pathological conditions such as 
wound healing (Sprugel et al., 1988) nerve regenera- 
tion (Baird et al., 1988), and cardiac infarction. 
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